Mucosal Immunogenic Compositions for Room-Temperature Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing injectable vaccines face challenges such as iatrogenic pain, safety risks for medical staff and patients, instability at ambient temperatures, and require strict refrigeration, limiting their widespread use and accessibility.
Innovation Solution
Development of immunogenic compositions using recombinant virus vectors formulated with PMAL-C16 or zwitterionic surfactants, which can be administered via mucosal routes and maintain stability at room temperature, incorporating pH buffering agents and stabilizing agents like sugars or polymers to enhance stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If injectable vaccines are used, then immune protection is achieved, but iatrogenic pain and safety risks occur
Solution Approach 1:
The patent replaces the mechanical injection system with a mucosal delivery system. The vaccine composition is administered orally or through other mucosal routes, eliminating needles and injection-related harms while delivering the immunogenic payload through the mucosal membrane for systemic immune protection.
Solution Approach 2:
The patent uses mucosal membranes (oral, nasal, pulmonary, etc.) as intermediary delivery routes. The vaccine composition interacts with mucosal-associated lymphoid tissues and antigen-presenting cells in the mucosa, serving as a mediator to induce immune responses without direct parenteral injection.
2Stability of the object's composition
If refrigeration is maintained for vaccine storage, then vaccine stability is preserved, but accessibility and widespread use are limited
Solution Approach 1:
The patent employs excipients and formulation technologies that change the physical and chemical parameters of the vaccine composition, enabling it to maintain stability at elevated temperatures (2-30°C) without refrigeration. This thermal parameter change allows the vaccine to withstand ambient conditions during transport and storage.
Solution Approach 2:
The patent incorporates stabilizing excipients and protective agents in the vaccine formulation before storage and transport. These pre-added components cushion and protect the immunogenic payload from thermal degradation and environmental stressors during distribution, eliminating the need for cold chain infrastructure.
3Ease of operation
If mucosal administration is used, then ease of administration is improved, but delivery efficiency may be reduced
Solution Approach 1:
The patent utilizes mucosal-associated lymphoid tissues (MALT), dendritic cells, and antigen-presenting cells in the mucosa as intermediary delivery targets. These natural immune sentinels in the mucosal lining efficiently capture and process the vaccine antigen, converting the ease of mucosal administration into effective immune activation.
Solution Approach 2:
The patent exploits the unique local immunological properties of different mucosal sites (oral, nasal, pulmonary, gastrointestinal). Each mucosal route provides access to specific lymphoid tissues and immune cell populations, allowing optimization of delivery efficiency for particular vaccine targets while maintaining overall ease of administration.
Data Source
AI summary
Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.